Shanghai Ruijikang Biopharmaceutical

Shanghai Ruijikang Biopharmaceutical is a biotechnology company dedicated to developing transformative gene therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). The company utilizes a proprietary AAV-based platform to deliver genetic payloads that target and degrade pathogenic protein aggregates, such as SOD1 and TDP-43. Founded in 2021 by experts from the Chinese Academy of Sciences, Ruijikang aims to address the significant unmet medical needs in conditions like ALS, Parkinson's, and Alzheimer's. Their lead candidate, RJK001, is currently in the IND-enabling phase and has shown promising results in investigator-initiated trials. The company is backed by prominent venture capital firms including Legend Capital and IDG Capital.